Study of Endothelial Progenitor Cell Dysfunction and Inflammation in Type 2 Diabetes with Cardiovascular Complications

What this Trial Is About

Researchers are investigating how endothelial progenitor cells EPCs, which help repair blood vessels, behave in people with type 2 diabetes T2D and cardiovascular complications. The study focuses on understanding how EPC dysfunction, influenced by abnormal cell signaling and chronic inflammation, contributes to the progression of atherosclerosis in T2D. A special sub-study will explore ways to improve EPC function by enhancing the activity of a key protein called endothelial nitric oxide synthase eNOS. Participants will have EPCs isolated from their blood for detailed analysis. The study includes groups of people with T2D without cardiovascular complications, those with T2D and coronary artery disease, and a control group without T2D. The sub-study will test whether increasing eNOS activity in EPCs can improve their ability to repair blood vessels. Various laboratory tests will measure gene expression, calcium signaling, inflammation markers, and EPC function both before and after gene enhancement. During the study, participants will provide blood and urine samples for EPC isolation and testing. Researchers will assess EPC dysfunction, inflammatory responses, and their capacity to mature into vascular cells over a period of 15 to 20 days. The sub-study will evaluate the effects of genetic enhancement on EPC function 72 hours after gene transfection. This comprehensive evaluation aims to better understand vascular complications in T2D and explore potential therapeutic strategies.

Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes